About Ubiquitin carboxyl-terminal hydrolase 17-like protein 23 (Fragment)
Ubiquitin carboxyl-terminal hydrolase 17-like protein 23 (Fragment) (USP17L23) is a protein
from Homo sapiens identified by UniProt accession
D6RBM5, 183 residues long.
MolForge cross-references it against 0 known binders and
21 disease associations.
Target properties
| Protein name | Ubiquitin carboxyl-terminal hydrolase 17-like protein 23 (Fragment) |
| UniProt accession | D6RBM5 |
| Gene | USP17L23 |
| Organism | Homo sapiens |
| Length | 183 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (21)
Diseases linked to this target (Open Targets).
- immunodeficiency 19 · score 0.04
- urate measurement · score 0.04
- combined immunodeficiency with skin granulomas · score 0.03
- immunodeficiency 73c with defective neutrophil chemotaxis and hypogammaglobulinemia · score 0.03
- severe combined immunodeficiency due to IKK2 deficiency · score 0.03
- ring chromosome Y · score 0.03
- X-Linked Combined Immunodeficiency Diseases · score 0.03
- severe combined immunodeficiency due to LAT deficiency · score 0.03
- obesity due to congenital leptin deficiency · score 0.03
- immunodeficiency 99 with hypogammaglobulinemia and autoimmune cytopenias · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-D6RBM5-F1 | alphafold | PREDICTED | 71.98 | — |
Amino-acid sequence (183 residues)
MEDDSLYLGG EWQFNHFSKL TSSRPDAAFA EIQRTSLPEK SPLSCETRVD LCDDLAPVAR QLAPREKLPL SSRRPAAVGA GLQNMGNTCY VNASLQCLTY TPPLANYMLS REHSQTCHRH KGCMLCTMQA HITRALHNPG HVIQPSQALA AGFHRGKQED AHEFLMFTVD AMEKACLPGH KQV
Explore Ubiquitin carboxyl-terminal hydrolase 17-like protein 23 (Fragment) with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets